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Abstract. Seven patients with minimal-change nephrotic
syndrome confirmed by renal biopsy were treated with
cyclosporin (CsA). Four patients had frequent relapses
and three others had primary steroid resistant nephrotic
syndrome. Corticosteroids were discontinued as soon as
CsA whole blood trough values of 200-500 ng/ml (RIA
method) were reached. A full remission, defined as com-
plete disappearance of proteinuria, was achieved in five
patients under this treatment. In the two other patients
proteinuria was reduced.
Two patients experienced an acute episode of dose-
dependent nephrotoxicity; however, overall renal func-
tion, as determined by the creatinine clearance, was
stable. Control biopsies in five patients after a mean treat-
ment period of 10 months showed no significant vascular
or interstitial toxicity.
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Introduction
Minimal-change nephrotic syndrome typically responds
to corticosteroids and generally has a good prognosis.
Spontaneous remissions are frequent. Three groups of
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patients, however, cause therapeutic problems, i.e., fre-
quent relapsers, patients with steroid-dependent disease,
and finally patients who are steroid and cytostatics resist-
ant. Long-term corticosteroid therapy in these patients is
followed by severe side-effects, e.g. cushingoid syndrome,
peptic ulcers, osteopathy and, especially in young
patients, reduced growth and delayed puberty.
Immunological studies in minimal-change nephrotic
syndrome suggest a defect in cellular immunoregulation
[1,2]. As CsA selectively inhibits the cellular immune
response [3], and successful pilot studies of its use in
minimal-change nephropathy were reported [4], a long-
term study was performed in seven adult patients with a
mean observation period of 18 months.
Patient Data and Treatment Protocol
Seven adult nephrotic patients (five males and two
females) with a mean age of 25 (17-43) years were studied
(Table 1). Proteinuria exceeded 3.5 g/day on at least two
consecutive measurements, plasma albumin was less than
25 g/1, and all patients had variable oedema. Minimal-
change nephropathy was confirmed by biopsy in all
patients during the nephrotic state. Control biopsies
could be obtained from five patients after a mean CsA
treatment of 10 months.
All patients had highly selective proteinuria, normal
GFR and normal complement concentrations. Severe
hypertension was present in one patient (patient no. 2),
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Table I. Patient data and pretreatment
Patient Initials Age/sex Age at
no. onset
(years)
Status Pretreatment Side-effects of corticosteroids
1
2
3
4
5
6
7
PS
UF
ML
AP
HK
DH
MF
18/M
31/F
17/M
43/F
20/M
18/M
27/M
1
5
3
42
14
15
25
Frequent relapser
Frequent relapser
Frequent relapser
Steroid-
cyclophosphamide
resistant
Infrequent relapser
Steroid-
cyclophosphamide
resistant
Steroid-
cyclophosphamide
resistant
Steroids;
cyclophosphamide
Steroids
Steroids
Steroids;
cyclophosphamide
Steroids
Steroids;
cyclophosphamide;
indometracin
Steroids;
cyclophosphamide
Osteoporosis, gastric ulcers, growth
retardation, pubertas tarda
Peptic ulcers, cushingoid syndrome
hypertension (?)
Osteoporosis, adrenal insufficiency, growth
retardation, pubertas tarda
Cushingoid syndrome, steroid acne
Gastritis, cushingoid syndrome, steroid acne
Cushingoid syndrome, steroid acne
Cushingoid syndrome, steroid acne
M = male; F = female
two patients had mild hypertension (patients no. 3 and 5).
Before the onset of this study three patients were on ster-
oid monotherapy (patients no. 2, 3 and 5), four patients
(patients no. 1, 4, 6 and 7) had pretreatment with a
steroid-cyclophosphamide combination.
All patients had steroid-related side-effects of varying
degree. CsA was given initially at a dose of 3-5 mg/kg
bodyweight twice daily. Steroids were gradually discon-
tinued when CsA whole blood trough values reached the
target therapeutic window of 200-500 ng/ml (RIA
method, Sandoz Ltd). No other immunosuppressive
drugs were given at the same time. Renal function, total
protein, proteinuria (Biuret method), type of proteinuria
(gradient gel electrophoresis), liver function and CsA
whole blood trough concentrations were checked twice a
week during the first 3 weeks. Later, the above-mentioned
laboratory controls were carried out every 3 weeks. CsA
doses were adapted to reach 200-500 ng/ml whole blood
trough levels.
Kidney biopsies were investigated by light microscopy,
by immunohistochemistry using the PAP method for the
demonstration of IgG, IgM, IgA, complement C3 and
fibrinogen, and also by electronmicroscopy according to
standard techniques.
Results
Five of seven patients (patients no. 1-5) achieved full
remission (proteinuria below 0.2 g/day) within 4 weeks
onset of CsA (Fig. 1). Mean cyclosporin dose was 4.3 mg/
g per day and the average blood concentration was
355 ng/ml during the treatment. Relapses of the nephrotic
syndrome occurred in all five patients when CsA was
stopped (patients no. 2, 4 and 5) or when blood CsA fell
below the therapeutic range (patients no. 1 and 3).
After 4 months of full remission with CsA in patient 2,
pre-existing arterial hypertension deteriorated and CsA
was stopped. Subsequently, hypertension was more easily
controlled, but 10 days later the nephrotic syndrome
recurred followed by pulmonary embolism due to deep
leg-vein and pelvic-vein thrombosis. After reintroduction
of CsA monotreatment, full remission was achieved and
hypertension could be controlled by converting-enzyme
inhibitors. Recurrences of the nephrotic syndrome were
found after 6 and 8 months of full remission in patients no.
1 and 3 when blood CsA fell below 100 and 200 ng/ml
respectively. On increasing the CsA doses, proteinuria
disappeared again with a return to normal serum protein.
In patient no. 3, gradient gel urine electrophoresis
showed a change to unselective proteinuria, and a control
biopsy showed a focal glomerular sclerosis. Patients no. 4
and 5 had relapses of their nephrotic syndrome when CsA
was stopped after 12 and 18 months of full remission.
The relapses occurred 2 weeks and 6 months respectively
after discontinuation of CsA treatment. Reintroduction
of CsA combined with prednisolone (1 mg/kg body
weight for 14 days, with steroids being tapered over 4
weeks) caused a second complete remission in both
patients.
The two non-responders (patients no. 6 and 7) had a
slight decrease in proteinuria during CsA therapy, and
oedema was more easily controlled. Immunosuppression
with CsA was discontinued after 6 and 10 months.
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Fig. 1. Changes of proteinuria during immunosuppressive pretreatment
and with cyclosporin. CsA, cyclosporin; CP, cyclophosphamide; St,
corticosteroids; In, indomethacin; • =CsA< 100 ng/ml.
Renal function did not change during the observation
period (Fig. 2). Mean creatinine clearance in all patients
remained stable (pretreatment: 115 + 13 vs post-treatment
112+11 ml/min) (Table 2). Two patients had transient
nephrotoxicity when CsA whole blood concentrations
exceeded 500 ng/ml. Creatinine clearances returned to
normal after CsA dose reduction.
Control biopsies from five patients after a mean treat-
ment of 10 months (Table 3) showed minimal or slight
focal interstitial fibrosis and tubular atrophy. One patient
had slight arteriolopathy. The morphologic lesions, how-
ever, were not typical and severe enough to be attributed
to CsA toxicity. Significant tubular toxicity was not
found. Other side-effects caused by CsA, e.g. hypertri-
chosis, gingival hyperplasia and tremor were slight and
could easily be reduced by dose reduction. There were no
signs of hepatotoxicity.
Discussion
The effect of CsA in minimal-change nephropathy has
been examined in only a few patients. Tejani [5] treated
five children with steroid-dependent, and four children
with steroid-resistant, minimal-change nephropathy CsA
dose 7 mg/kg bodyweight daily) for 2 months. In all
patients, complete remission was achieved for at least 10
months. Meyrier and co-workers [6] induced complete
remissions in three adults with 12-42 days of CsA therapy
(5 mg/kg bodyweight; trough levels 125-750 ng/ml).
Brodehl et al [7,8] reported five children with frequently
relapsing disease, where CsA (trough levels 200-400 ng/
ml) reduced the number of relapses and prednisolone
Fig. 2. Creatinine clearance before and during treatment with CsA.
requirement; two patients reached full remissions for 6
months under CsA treatment.
In the present study, CsA maintained long-lasting
remissions in five of seven adult patients with minimal-
change nephrotic syndrome. Of the responding patients,
four were frequent relapsers and one had steroid and
cyclophosphamide resistance. Especially in our young
patients (patients no. 1 and 3) with long-term cortico-
steroid pretreatment, there was substantial benefit with
this therapy: puberty commenced, bone growth restarted
and the steroid-induced cushingoid syndrome resolved
(Fig. 3).
However, all CsA responders became CsA dependent.
Relapses of their nephrotic syndrome occurred between
10 days and 6 months after withdrawal of CsA, but second
remissions could be achieved in all those patients with
reintroduction of the drug. The exact mechanism of
action of CsA remains elusive. The beneficial effect of this
T-cell-specific agent, however, favours the hypothesis of a
T-cell-mediated disorder in minimal-change nephropathy
[2,9-14].
CsA is increasingly used for the treatment of various
autoimmune disorders. As compared with conventional
immunosuppression, CsA carries no risk of osteoporosis,
myelotoxicity, growth and sexual retardation or terato-
genicity. However, CsA may cause severe side-effects
including nephrotoxicity, hypertension and occasionally
hepatotoxicity. Thus, in non-fatal autoimmune diseases
the risk and benefit of CsA therapy have to be evaluated.
Dose-dependent nephrotoxicity is well known in all
groups of patients treated with CsA including those with
autoimmune diseases [15-17]. There was a slight increase
of morphological scores in our control biopsies during
treatment, but these findings were not so pronounced as
to indicate CsA toxicity, and GFR remained unchanged
during the observation period of 6-30 (mean 18) months.
The fact that no significant nephrotoxicity was found in
our patients may be due to two reasons: (a) slow increase
in CsA dose; (b) low dose and low trough CsA concen-
tration.
Table 2. Clearance, proteinuria and clinical course under CsA
Patient Creatininc clearance*
no. (ml/min per 1.73 m2)
B U
Serum protein*
(g/D
B U
Proteinuria*
(g/day)
B U
Duration of
CsA treatment
(months)
Mean CsA trough**
level (ng/ml)
full blood
Outcome
123 + 23 111 ±8.5 32.6 ±1.8 70.2 ±3.5 5.7±l. l 30 439 ±274
2
3
4
5
6
7
Mean
92 ±10
II2±I6
IO5±I3
119+17
I37±22
II7±8
II5±I3
99±I2
113±I4
104+ 10
IIO±15
106±ll.5
138 ±8.5
112±U
29.5±l.l
41.2±3.l
39 + 2.9
37 ±3.0
46.2 ±4.1
46.6 ±1.6
38.9 ±5.9
65 ±2.8
63.5 ±3.0
67.5 ±2.4
68±3.l
49 ±3.2
50 ±3.7
61.9±8.l
9.6 ±0.9
5.8 ±1.2
8.7 ±1.3
9.2 ±1.0
6.1 ± 1.2
6.5±l.3
7.4 ±1.6
0
0
0
0
4.2+1.1
4.5 ±1.6
23
23
18
17
10
6
18.1+8.1
332±164
279±15I
173 ±42
274 ±66
326 ±126
663 ±147
Remission, recidive when CsA blood level
< 200 ng/ml. 2. remission with CsA; grew
10.5 cm
Remission, recidive after stopping CsA for
severe hypertension. 2. remission with CsA
Remission, relapse when CsA blood level
< 100 ng/ml. 2. remission with CsA; grew
10cm
Remission, relapse 6 months after stop of
CsA. 2. remission
Remission, relapse I month after stop of
CsA. 2.: remission
Slight reduction of proteinuria; stop of CsA
after 10 months
Slight reduction of proteinuria; stop of CsA
after 10 months
•Mean of 3 consecutive measurements; "mean of all trough level measurements during treatment; B, before treatment with CsA; U, after 2 months under CsA
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Table 3. Results of renal control biopsies before and during CsA
73?
Patient No. of Obsolescent Segmental focal
no. glomeruli glomcruli glomerulosclerosis
Aneriolopathy
(score 0-4)
0
1
I
0
0
0
0
2
0
0
interstitial
fibrosis and
tubular atrophy
(score 0-4)
1
2
0
I
0
2
1
I
0
1
Interstitial
infiltrates
0
2
0
0
0
1
0
0
0
0
Immuno-
ftuorescence
lgM
IgM
neg.
IgM
IgM
neg.
IgM
neg. -
neg.
JgM
1 B
D
2 B
D
3 B
D
4 B
D
5 B
D
10
5
2
13
10
f>
P
4
3
B = before CsA; D = during CsA
Score: 0= not present; I =minimal; 2=slight: 3=medium severe; 4=severe
0911965
Fig. X Patient no. 3 before and during therapy with CsA.
CsA doses were considerably lower than in auto-
immune patients in whom CsA toxicity has been reported
[16,17].
Our data indicate that CsA may be effective and safe in
minimal-change nephrotic syndrome. Strict control of
blood CsA, and renal and hepatic function are necessary
to prevent toxicity. The use of CsA in adult patients with
minimal-change nephropathy is suggested in the follow-
ing conditions: (a) inadequate response with conventional
immunosuppression; and/or (b) severe side-effects due to
conventional immunosuppression.
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